267 results on '"Nguewa, Paul"'
Search Results
2. Therapeutic Applications of Cyclodextrins Against Trypanosomiases and Leishmaniasis
3. Mixed micelles and gels of a hydrophilic poloxamine (Tetronic 1307) and miltefosine: Structural characterization by small-angle neutron scattering and in vitro evaluation for the treatment of leishmaniasis
4. Host cell proteins modulated upon Toxoplasma infection identified using proteomic approaches: a molecular rationale
5. Promising aryl selenoate derivatives as antileishmanial agents and their effects on gene expression
6. Selenium and protozoan parasitic infections: selenocompounds and selenoproteins potential
7. A rapid and low-cost protocol for the detection of B.1.1.7 lineage of SARS-CoV-2 by using SYBR Green-based RT-qPCR
8. The main post-translational modifications and related regulatory pathways in the malaria parasite Plasmodium falciparum: An update
9. The host mTOR pathway and parasitic diseases pathogenesis
10. Improving the miltefosine efficacy against leishmaniasis by using different nanoassemblies made from surfactants or amphiphilic antimony (V) complex
11. Contributors
12. Correction to: A rapid and low‑cost protocol for the detection of B.1.1.7 lineage of SARS‑CoV‑2 by using SYBR Green‑based RT‑qPCR
13. Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions
14. Advances in Biomedical Applications of Solution Blow Spinning
15. Characterization of Leishmania Parasites Isolated from Naturally Infected Mammals
16. BRCT Domains: Structure, Functions, and Implications in Disease—New Therapeutic Targets for Innovative Drug Discovery against Infections
17. Ameliorating the antiparasitic activity of the multifaceted drug ivermectin through a polymer nanocapsule formulation
18. The most prominent modulated annexins during parasitic infections
19. Microbiome Control in the Prevention and Early Management of Cancer
20. Supplementary Figure 4 from Inhibitor of Differentiation-1 as a Novel Prognostic Factor in NSCLC Patients with Adenocarcinoma Histology and Its Potential Contribution to Therapy Resistance
21. Supplementary Figure 2 from Inhibitor of Differentiation-1 as a Novel Prognostic Factor in NSCLC Patients with Adenocarcinoma Histology and Its Potential Contribution to Therapy Resistance
22. Supplementary Figure 1 from Inhibitor of Differentiation-1 as a Novel Prognostic Factor in NSCLC Patients with Adenocarcinoma Histology and Its Potential Contribution to Therapy Resistance
23. Supplementary Figure 5 from Inhibitor of Differentiation-1 as a Novel Prognostic Factor in NSCLC Patients with Adenocarcinoma Histology and Its Potential Contribution to Therapy Resistance
24. Supplementary Figure 3 from Inhibitor of Differentiation-1 as a Novel Prognostic Factor in NSCLC Patients with Adenocarcinoma Histology and Its Potential Contribution to Therapy Resistance
25. Burden of infectious disease studies in Europe and the United Kingdom: a review of methodological design choices
26. Burden of disease attributable to risk factors in European countries: a scoping literature review
27. The inhibitor of differentiation isoform Id1b, generated by alternative splicing, maintains cell quiescence and confers self-renewal and cancer stem cell-like properties
28. Repurposing the Antibacterial Agents Peptide 19-4LF and Peptide 19-2.5 for Treatment of Cutaneous Leishmaniasis
29. The BRCT Domain from the Homologue of the Oncogene PES1 in Leishmania major (LmjPES) Promotes Malignancy and Drug Resistance in Mammalian Cells
30. The Defensive Interactions of Prominent Infectious Protozoan Parasites: The Host’s Complement System
31. Topical treatment of L. major infected BALB/c mice with a novel diselenide chitosan hydrogel formulation
32. miRNAs in the regulation of mTOR signaling and host immune responses: The case of Leishmania infections
33. Differential Tumor Expression of Inhibitor of Differentiation-1 in Prostate Cancer Patients With Extreme Clinical Phenotypes and Prognostic Implications
34. Novel hybrid selenosulfonamides as potent antileishmanial agents
35. Thermosensitive hydrogels of poly(methyl vinyl ether-co-maleic anhydride) – Pluronic® F127 copolymers for controlled protein release
36. Programmed Cell Death in Protozoa: An Evolutionary Point of View. The Example of Kinetoplastid Parasites
37. Mining the Proteome of Toxoplasma Parasites Seeking Vaccine and Diagnostic Candidates
38. Immunomodulatory Potential of Non-Classical HLA-G in Infections including COVID-19 and Parasitic Diseases
39. In Leishmania major, the Homolog of the Oncogene PES1 May Play a Critical Role in Parasite Infectivity
40. Unravelling data for rapid evidence-based response to COVID-19: a summary of the unCoVer protocol
41. Discovery and Validation of Lmj_04_BRCT Domain, a Novel Therapeutic Target: Identification of Candidate Drugs for Leishmaniasis
42. Highlighting the interplay of microRNAs fromLeishmaniaparasites and infected-host cells
43. Activity of Anti-Microbial Peptides (AMPs) against Leishmania and Other Parasites: An Overview
44. Sunitinib reduces tumor hypoxia and angiogenesis, and radiosensitizes prostate cancer stem-like cells
45. Potential therapeutic targets shared between leishmaniasis and cancer
46. Leishmanial apolipoprotein A-I expression: a possible strategy used by the parasite to evade the host’s immune response
47. B.1.1.7 became the dominant variant in Lebanon
48. Potential therapeutic targets shared between leishmaniasis and cancer
49. A Rapid and Low-Cost protocol for the detection of B.1.1.7 lineage of SARS-CoV-2 by using SYBR Green-Based RT-qPCR
50. Emergence and fast spread of B.1.1.7 lineage in Lebanon
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.